PCM
TGTX icon

Penserra Capital Management’s TG Therapeutics TGTX Stock Holding History

Penserra Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,855
Closed -$1.89M – 1132
2025
Q1 		$1.89M Buy
+47,855
New +$1.61M 0.03% 313
2024
Q4 		– Sell
-98,144
Closed -$2.29M – 1195
2024
Q3 		$2.29M Buy
98,144
+73,211
+294% +$1.6M 0.05% 272
2024
Q2 		$444K Buy
+24,933
New +$398K 0.01% 590

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Penserra Capital Management's TGTX Position: Q2 2025 in Review

Penserra Capital Management sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 47,855 shares — an estimated $1.89M sold.

Penserra Capital Management first reported a position in TGTX in Q2 2024 and held it in 3 quarters. The position peaked at $2.29M in Q3 2024. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Penserra Capital Management reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Penserra Capital Management sold 47,855 TG Therapeutics shares in Q2 2025, an estimated $1.89M.
  • Penserra Capital Management first reported a position in TG Therapeutics in Q2 2024 and held it in 3 quarters.
  • Penserra Capital Management's TG Therapeutics position peaked at $2.29M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Penserra Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.